{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:58:59Z","timestamp":1781308739858,"version":"3.54.1"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,1,4]],"date-time":"2010-01-04T00:00:00Z","timestamp":1262563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To determine if paroxetine <jats:italic>versus<\/jats:italic> non\u2010paroxetine selective serotonin reuptake inhibitors (SSRIs) prescribing changed after the June 2003 FDA Paroxetine Public Health Advisory (PPHA) and if antidepressant and antipsychotic prescribing changed after the February 2004 FDA Advisory Committee Meeting (FDACM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ecologic analysis using estimates of patients dispensed antidepressants and antipsychotics, census data, and promotional spending data. Data sources were SDI: Vector One\u00ae, US Census, and IMS Health\u00ae. Measures were monthly use levels (number of patients dispensed antidepressants, antipsychotics, paroxetine, and non\u2010paroxetine SSRIs prescriptions by age group per population count). Percent changes pre\u2010 to post\u2010PPHA were used to assess changes in paroxetine <jats:italic>versus<\/jats:italic> non\u2010paroxetine SSRIs prescribing. Interrupted time series (ITS) analysis was performed to examine use level changes post\u2010FDACM by drug groups (all antidepressants and all antipsychotics).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Post\u2010PPHA mean paroxetine use levels decreased for all age groups (range: 5.5\u201334.1%). Mean non\u2010paroxetine SSRIs use levels increased (range: 4.6\u201317.1%). Post\u2010PPHA changes were greatest for 6\u201312 and 13\u201317 year olds. Decreased mean antidepressant drug use levels from pre\u2010 to post\u2010FDACM were observed in all groups under 25 years old. A statistically significant decrease in the slopes from pre\u2010 to post\u2010FDACM was observed for persons aged 13\u201317 and 18\u201324 years. The difference between the forecasted mean use level and the observed mean use level (in 12\u2010month intervals) was statistically significant for all ages combined (\u2212107.26; 95% CI: \u2212166.32, \u221248.20) and 1\u20135 (\u22123.1; 95% CI: \u22124.62, \u22121.58), 6\u201312 (\u221236.02; 95% CI: \u221262.92, \u22129.12) and 25 years, and older groups (\u221283.17; 95% CI: \u2212153.95, \u221212.39). For all age groups, decreases in the slopes of antipsychotic drugs use from pre\u2010 to post\u2010FDACM were observed, although these slope changes were not statistically significant. The difference between the forecasted mean antipsychotic drugs use level and the observed mean use level (in 12\u2010month intervals) was statistically significantly lower for all age groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Antidepressant use changed post\u2010PPHA and \u2010FDACM, with a differential pattern by age. There was no evidence of increased antipsychotic use post\u2010FDACM. Ecologic data cannot determine if changes were due to depression not treated with medications or the prescribing of fewer antidepressants for other conditions. Published in 2009 by John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1886","type":"journal-article","created":{"date-parts":[[2010,1,4]],"date-time":"2010-01-04T16:12:01Z","timestamp":1262621521000},"page":"158-174","source":"Crossref","is-referenced-by-count":35,"title":["Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions"],"prefix":"10.1002","volume":"19","author":[{"given":"Carol A.","family":"Pamer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek A.","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010te","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Rochester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Governale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Mosholder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,4]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"HetrickSE McKenzieMS SindahlP ProctorM.Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents (review). Cochrane Database of Systematic Reviews2007; Issue 3 Art. No.: CD004851."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050730"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.25"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.3.332"},{"key":"e_1_2_1_6_2","unstructured":"Food and Drug Administration.FDA Talk Paper: FDA statement regarding antidepressant Paxil for pediatric population (T03\u201043). Release date: June 19 2003; Website address:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PublicHealthAdvisories\/ucm168828.htmAccessed July 2009."},{"key":"e_1_2_1_7_2","unstructured":"Food and Drug Administration.FDA Public Health Advisory: reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). Release date: October 27 2003; Website address:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PublicHealthAdvisories\/ucm168828.htmAccessed July 2009."},{"key":"e_1_2_1_8_2","unstructured":"Food and Drug Administration. February 2 2004; Psychopharmacologic Drugs Advisory Committee Meeting Summary Minutes. Website address:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/minutes\/4006M1_ Final.htmAccessed July 2009."},{"key":"e_1_2_1_9_2","unstructured":"Food and Drug Administration.FDA Public Health Advisory: worsening depression and suicidality in patients being treated with antidepressants. Release date: March 22 2004; Website address:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PublicHealthAdvisories\/ucm161696. htmAccessed July 2009."},{"key":"e_1_2_1_10_2","unstructured":"Food and Drug Administration. September 14 2004; Psychopharmacologic Drugs Advisory Committee Meeting transcripts. Website address:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/transcripts\/2004\u20104065 T2.htmpp. 114\u2013123. Accessed March 2008."},{"key":"e_1_2_1_11_2","unstructured":"Food and Drug Administration.FDA Public Health Advisory: suicidality in children and adolescents being treated with antidepressant medications. Release date: October 15 2004; Website address:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PublicHealthAdvisories\/ucm161679.htmAccessed July 2009."},{"key":"e_1_2_1_12_2","first-page":"905","article-title":"Suicide trends among youths and young adults aged 10\u201324 years\u2014United States, 1990\u20132004","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR"},{"key":"e_1_2_1_13_2","unstructured":"HeronMP HoyertDL MurphySL XuJQ KochanekKD Tejada\u2010VeraB. Deaths: final data for2006; National vital statistics reports; 57(14):30. Hyattsville MD: National Center for Health Statistics. Website addresshttp:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr57\/nvsr57_14. pdfAccessed August 2009."},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.161.7.690"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.4.466"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07030454"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.6.884"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07010007"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07010205"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2007.5"},{"key":"e_1_2_1_21_2","unstructured":"Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Website:http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ucm129662.htmAccessed: July2009."},{"key":"e_1_2_1_22_2","unstructured":"US Census Bureau. Monthly Postcensal Resident Population by single year of age sex race and Hispanic origin. Website:http:\/\/www.census.gov\/popest\/national\/asrh\/2006_nat_res.htmlAccessed June 29 2007."},{"key":"e_1_2_1_23_2","volume-title":"Time Series Analysis: Univariate and Multivariate Methods","author":"Wei WWS","year":"1990"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.4135\/9781412984607"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A109"},{"key":"e_1_2_1_27_2","unstructured":"FDA. Psychopharmacologic Drugs Advisory Committee Meeting February 2 2004; \u201cDrug Utilization for Selected Antidepressants Among Children & Adolescents in the US\u201d Dr. Gianna Rigoni PharmD MS FDA. Website:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/slides\/4006s1.htmAccessed July 2009."},{"key":"e_1_2_1_28_2","unstructured":"FDA. Psychopharmacologic Drugs Advisory Committee Meeting June 9 2009; briefing materials. Website:http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Psychophar macologicDrugsAdvisoryCommittee\/UCM164423.pdfpp. 7 13\u201315. Accessed July 2009."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1886","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1886","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:20:32Z","timestamp":1700580032000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1002\/pds.1886"],"URL":"https:\/\/doi.org\/10.1002\/pds.1886","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,4]]}}}